Concepedia

Incomplete Crossover Designs

Incomplete Crossover Designs is a type of crossover design in which not all participants receive all treatments within the sequence, thereby differing from complete crossover designs by omitting certain treatment periods or arms for logistical, ethical, or practical reasons.

24

Publications

662

Citations

119

Authors

70

Institutions

Publications per year

2017–2026

3

Parents

Publications

24

Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: A randomised dose-ranging study

Christian Vogelberg, Michael Engel, Petra Moroni-Zentgraf et al. · Respiratory Medicine · 2014 · 101 citations · Full text

, , +16

Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials

François Maltais, Sally Singh, Alison Donald et al. · Therapeutic Advances in Respiratory Disease · 2014 · 72 citations · Full text

, , +16

A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers

Paul Martin, Mike J. Warwick, Aaron Dane et al. · Clinical Therapeutics · 2003 · 61 citations

, , +12

The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis

Philippe Bareille, Robert Murdoch, Jane Denyer et al. · International Journal of Clinical Pharmacology and Therapeutics · 2013 · 42 citations

, , +17

The effect of motilin agonist ABT‐229 on gastro‐oesophageal reflux, oesophageal motility and lower oesophageal sphincter characteristics in GERD patients

Joost A. van Herwaarden, Samsom, Van Nispen et al. · Alimentary Pharmacology & Therapeutics · 2000 · 37 citations · Full text

, , +16

1–5 of 24

Authors

119

  1. AD
    Aaron Dane

    AstraZeneca (United Kingdom), United Kingdom

    2 publications · 91 citations

    2

    h-index

  2. MC
    M. Clark

    University of Illinois Urbana-Champaign, United States

    1 publications · 14 citations

    1

    h-index

  3. RP
    Robert P. Hunter

    Kansas State University, United States

    1 publications · 24 citations

    1

    h-index

  4. WZ
    Wei Zheng

    University of Illinois Chicago, United States

    1 publications · 11 citations

    1

    h-index

  5. ML
    Miglė Leonavičiūtė-Klimantavičienė

    Boehringer Ingelheim (Germany), Germany

    1 publications · 101 citations

    1

    h-index

1–5 of 119

Institutions

70

  1. Boehringer Ingelheim (United States)

    Ridgefield, United States

    3 h-index

    5 publications

    160 citations

  2. Boehringer Ingelheim (Germany)

    Ingelheim, Germany

    3 h-index

    7 publications

    448 citations

  3. AstraZeneca (United Kingdom)

    Cambridge, United Kingdom

    2 h-index

    9 publications

    394 citations

  4. Novartis (Switzerland)

    Basel, Switzerland

    2 h-index

    3 publications

    45 citations

  5. GlaxoSmithKline (United Kingdom)

    London, United Kingdom

    2 h-index

    4 publications

    198 citations

  6. Abbott Fund

    Chicago, United States

    2 h-index

    7 publications

    175 citations

  7. Rēzeknes Augstskola

    Rēzekne, Latvia

    1 h-index

    1 publications

    101 citations

  8. Medical University of Vienna

    Vienna, Austria

    1 h-index

    1 publications

    42 citations

1–8 of 70

Venues

  1. Alimentary Pharmacology & Therapeutics

    3 publications · 96 citations

    3

    h-index

  2. The Journal of Clinical Pharmacology

    2 publications · 53 citations

    2

    h-index

  3. Biometrika

    2 publications · 35 citations

    2

    h-index

  4. Therapeutic Advances in Respiratory Disease

    1 publications · 72 citations

    1

    h-index

  5. 1

    h-index

1–5